

8 July 2026

SHAREWISE WEBINAR PRESENTATION

Mach7 Technologies Limited (“Mach7” or the “Company”) (ASX:M7T), a healthcare software company that enables health systems to securely store, access and share diagnostic images across disparate systems, provides a copy of a presentation that will be delivered by the Managing Director and CEO Teri Thomas at a Sharewise investor webinar today.

Please use the link below to register for the webinar which will commence at **9am AEST, Wednesday 8 July 2026**.

https://zoom.us/webinar/register/3017824416590/WN_0GmIKLw_TQaDzBweOKhWBw

Released on authority of the Board by Teri Thomas, Managing Director and Chief Executive Officer.

For more information, contact:

Investor Relations
Françoise Debelak Dixon
+61 (0) 412 292 977
ir@mach7t.com

About Mach7 Technologies:

Mach7 Technologies (ASX:M7T) provides enterprise imaging software that enables healthcare organisations to manage, access and share diagnostic imaging data across complex environments. The Mach7 platform combines a Vendor Neutral Archive (VNA), the eUnity Enterprise Diagnostic Viewer and the Flamingo suite of modules, expanding capabilities across workflow, interoperability and data management to support a more complete view of the patient record. Together, these capabilities position Mach7 to support the evolution of enterprise imaging toward a more unified, longitudinal patient record that integrates clinical data and diagnostic imaging. Built for interoperability and scalability, Mach7 supports emerging AI-driven clinical workflows and is increasingly aligned with leading cloud ecosystems, including Amazon Web Services (AWS). The Company serves a global customer base including integrated delivery networks, national health systems and specialist imaging providers. Visit mach7t.com for more information.



Mach7 Technologies Limited (ASX:M7T) ABN: 26 007 817 192
Registered Office: Suite 2, Level 11, 385 Bourke St, Melbourne, VIC 3000
T: +61 1300 384 692
www.mach7t.com

The background of the slide features three medical professionals (two men and one woman) in white lab coats, smiling and looking at a laptop. Overlaid on the image are various digital and medical graphics, including a glowing brain, a heart, a cross-section of a brain, and a pink flamingo in the bottom right corner. The overall theme is medical technology and innovation.

Introducing Mach7 Sharewise Conference

8 July 2026

OUR VISION

To be the global imaging EMR.

We win by completing the patient picture with the patient's pictures, better than anyone else.

Pixels to point of care.

Key industry trends

Workforce and automation

Shortages in medical staff drive adoption of AI and automation to sustain productivity and reduce workload.

Interoperability & data integration

Open APIs and EMR interoperability are critical for seamless imaging access and data liquidity across systems.

Cybersecurity and resilience

Security is now essential for operational continuity and patient trust under increasing cyber threats.

Cloud and remote workflows


Hybrid cloud and edge architecture enable fast, scalable and remote diagnostic-quality healthcare access.

Expanded product suite




Vendor Neutral Archive

- ✓ Consolidate ALL images across the enterprise
- ✓ Modular and flexible
- ✓ Allows organisations to leverage existing IT infrastructure
- ✓ Store in native format or wrap in DICOM
- ✓ On-premise or via Cloud infrastructure



Flamingo Architecture

- ✓ AI enablement within the software plus platform for creation of AI
- ✓ Modern and expanded API layer
- ✓ Dynamic Policy Engine for intelligent orchestration, custom routing, and other customisation capabilities
- ✓ Built to drive cloud migration ROI
- ✓ Reduce implementation times and costs
- ✓ **First customer signed in Q2 FY26**



eUnity Enterprise Diagnostic Viewer

- ✓ Zero footprint HTML-5 viewer; 100% fidelity
- ✓ Virtual aggregation of imaging data across the enterprise
- ✓ Expanded 3D: MIP/MPR/Mammography/Pet CT
- ✓ Image enable the EMR and patient portals
- ✓ Image enablement for downtime PACS solution
- ✓ Research and AI test platform
- ✓ Digital Pathology in development



Differentiators



1

End-to-end modular architecture for data independence & sovereignty

Vendor Neutral Architecture allows customers full control and unrestricted access to their data, with modular components.

2

AI & workflow automation drives advanced orchestration

Intelligent rules-based routing, meta-data driven orchestration and data availability supporting complex workflows and AI development.

3

Security & compliance

Security is critical. Mach7's BitSight Security Rating reached 750 ("advanced" rating) above industry average of 730

4

Speed & performance

Hybrid cloud architecture delivers sub-second image access without costly infrastructure overhead.

5

Price-to-performance value


Mach7 offers enterprise-class capabilities at unmatched value, recognised for cost efficiency.

H1 FY26 Financial Review

Predominantly recurring revenue, lower cost base, strong balance sheet



- ① Recurring revenue base represents 85% of total revenue, 78% OPEX.
- ② Reduced operating expenses by 6%
- ③ Strong financial position with cash of A\$18.5M and no debt providing flexibility to execute commercial strategy.
- ④ Improvement in operating cash flow as moved through H1 FY26 with Mach7 operating cash flow positive in Q2 FY26.



Moving from archive to architecture

Executing deliberate transition, positioning imaging as core layer of patient record.



Foundations for durable profitable growth in place.

Execution focus areas going into FY27

1

Sales momentum

Improving with structured pipeline.

2

Delivery execution

Execution improving and timelines shortening via new archetype structures, technology and the use of AI.

3

Partner leverage

Expanding paths to markets, growth in pipeline, and industry exposure

4

Leadership and organisational readiness

CTO appointment, refreshed performance team aligned with strategy, culture of customer focus, urgency and innovation.

5

Cost and structural readiness

Reset supporting operating leverage, use of technology to do more with less, cut waste, AI and ROI integrated into budgeting.

Contact Us

Investor Relations, Mach7

Françoise Debelak Dixon

+61 (0) 412 292 977

ir@mach7t.com

Registered Office: Suite 2, Level 11, 385 Bourke St,
Melbourne, VIC 3000

This document was authorised for release to the
ASX by Teri Thomas, Managing Director and Chief
Executive Officer

Mach7 Technologies

Disclaimer

“Forward looking” statements



Summary of information: This presentation contains general and background information about Mach7 Technologies Limited (“M7T”) activities current as at the date of the presentation and should not be considered to be comprehensive or to comprise all the information that an investor should consider when making an investment decision. This presentation is not a prospectus, disclosure document, product disclosure statement or other offering document under Australian law or under any other law. The presentation does not purport to contain all the information that a prospective investor may require in assessing a possible investment in M7T nor does it contain all the information which would be required in a prospectus prepared in accordance with the requirements of the Corporations Act 2001 (Cth). The information provided is in summary form, has not been independently verified, and should not be considered to be comprehensive or complete. It should be read solely in conjunction with the oral briefing provided by M7T and all other documents provided to you by M7T. The information in this presentation remains subject to change without notice. M7T is not responsible for providing updated information and assumes no responsibility to do so.

Not financial product advice: This financial information provided in this presentation is for information purposes only. The information contained in this presentation is of a general nature only and is not a financial product, investment advice or a recommendation to acquire M7T securities and has been prepared without taking into account the objectives, financial situation or needs of any person or entity. Before making an investment decision prospective investors should consider the appropriateness of the information having regard to their own objectives, financial situation and needs, and seek legal, taxation and financial advice appropriate to their jurisdiction and circumstances. M7T is not licensed to provide financial product advice in respect of its securities or any other financial products. Cooling off rights do not apply to the acquisition of M7T securities. M7T assumes that the recipient is capable of making its own independent assessment, without reliance on this document, of the information and potential investment and will conduct its own investigation.

Disclaimer: M7T and its related bodies corporate and each of their respective directors, agents, officers, employees and advisors expressly disclaim, to the maximum extent permitted by the law, all abilities (however, caused, including negligence) in respect of, make no representations regarding, and take no responsibility for, any part of this presentation and make no representation or warranty as to the currency, accuracy, reliability or completeness of any information, statements, opinions, conclusions or representations contained in this presentation. In particular, this presentation does not constitute, and shall not be relied upon as, a promise, representation, warranty or guarantee as to the past, present or future performance of M7T.

Future performance: This presentation contains certain forward-looking statements and opinions. The forward-looking statements, opinions and estimates provided in this presentation are based on assumptions and contingencies which are subject to change without notice, as are statements about market and industry trends, which are based on interpretations of current market conditions. Forward-looking statements, including projections, forecasts and estimates, are provided as a general guide only and should not be relied on as an indication or guarantee of future performance and involve known and unknown risks, uncertainties and other factors, many of which are outside the control of M7T. Past performance is not necessarily a guide to future performance and no representation or warranty is made as to the likelihood of achievement or reasonableness of any forward looking statements or other forecast.

Risks: An investment in M7T securities is subject to investment and other known and unknown risks, some of which are beyond the control of M7T. You should have regard to the ‘Key Risks’ section of this presentation which outlines some of these risks.

Not an offer: This presentation is not, and should not be considered as, an offer or an invitation to acquire securities in M7T or any other financial products and neither this document nor any of its contents will form the basis of any contract or commitment. This presentation is not a prospectus. Offers of securities in M7T will only be made in places which, or to persons to whom it would be lawful to make such offers. This presentation must not be disclosed to any other party and does not carry any right of publication. Neither this presentation nor any of its contents may be reproduced or used for any other purpose without the prior written consent of M7T.

No distribution in the US: This presentation is not an offer of securities for sale in the United States. Any securities to be issued by M7T have not been and will not be registered under the US Securities Act of 1933, as amended (the “US Securities Act”) and may not be offered or sold in the United States absent registration or an exemption from registration under the US Securities Act. No public offer of the securities is being made in the United States and the information contained herein does not constitute an offer of securities for sale in the United States. This presentation is not for distribution directly or indirectly in or into the United States or to US persons.

Monetary values: Unless otherwise stated, all dollar values are in Australian dollars (AUD\$). The information in this presentation remains subject to change without notice.

Sophisticated and professional investor: By attending this presentation, you present and warrant that (i) if you are in Australia, you are a person to whom an offer of securities may be made without a disclosure document as defined in the Corporation Act 2001 (Cth) (“Corporation Act”) on the basis that you are exempt from the disclosure requirements of Part 6D.2 in accordance with Section 708(8) or 708(11) of the Corporations Act; (ii) if you are in the United States, you are a qualified institutional buyer (as defined under Rule 144A Under the U.S. Securities Act; (iii) if you are outside Australia and the United States, you are a person to whom an offer and issue of securities can be made outside Australia without registration, lodgement or approval of a formal disclosure document or other filing in accordance with the laws of that foreign jurisdiction. If you are not such a person, you are not entitled to attend this presentation. Please return this presentation and any copies and do not provide this presentation to any other person.

No distribution: Distribution of this presentation may be restricted by law. Persons who come into possession of this presentation should seek advice on and observe any such restrictions. Any failure to comply with such restrictions may constitute a violation of applicable security laws.